Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms.
| INTRODUCTION
Castleman disease (CD) is a rare lymphoproliferative disorder thought to be mediated via autoinflammation, cytokine release, and viral coinfections. 1 Castleman disease represents a heterogeneous group of diseases and is stratified based on centricity and pathology. Two well-defined clinical subtypes include localized or unicentric Castleman disease (UCD) and systemic or multicentric Castleman disease (MCD), and 3 main histological variants consist of hyaline vascular type (80-90%), plasma cell type (10-20%) and mixed type (<5%).
2,3
Multicentric Castleman disease can further be subdivided by the presence or absence of viral co-infection with human herpes virus-8
(HHV-8) and human immunodeficiency virus (HIV). Conventionally, the prognosis for UCD is excellent whereas the outlook for MCD is worse, 4 typically when associated with HIV and HHV-8.
The most common presenting complaint of UCD is isolated lymphadenopathy, although symptoms related to mass effects on surrounding structures may be present. A systematic review of 278 cases of UCD identified that the mean size of involved lymph nodes at baseline was 5.5 cm, compared to 3.8 cm for MCD cases. 5 The UCD case presented here had a baseline size of 6 cm. Multicentric Castleman disease commonly presents with systemic symptoms including traditional "B symptoms" such as fever, night sweats, and weight loss, along with generalized lymphadenopathy and splenomegaly.
The understanding of the pathogenesis of CD remains limited. Albeit CD had been considered to originate from polyclonal sources, mainly HIVand HHV-8 driven, recent evidence suggests that at least a proportion of cases has a monoclonal origin. [6] [7] [8] On the basis of recent therapeutic evidence, excessive cytokine release has gained attention as the key mechanism of pathogenesis as well as symptomatology. The dysregulation of interleukin-6 (IL-6) has been implicated in both UCD and MCD, and hypersecretion of IL-6 by germinal center B-cells is considered to be responsible for systemic manifestations. 9 Interleukin-6 regulates T-cell function, acute phase reaction, and terminal B-cell differentiation.
10,11
The optimal therapeutic strategy for MCD is unclear. A range of systemic therapies including steroids, cytotoxic chemotherapy-single agent, or combination regimens such as CHOP, anti-CD20 monoclonal antibodies, bortezomib, antiviral agents, and IL-6 inhibitors such as tocilizumab have been used with varying degrees of success. 4, 12 The standard of care for UCD is surgical resection, with 10-year OS rates exceeding 95%. 
| DISCUSSION/CONCLUSION
Tocilizumab is a recombinant, humanized monoclonal antibody that blocks the IL-6 receptors, both soluble and membrane-bound, and hence impedes downstream intracellular signalling. 15, 16 Promising results have been reported with the use of tocilizumab in patients with MCD. A major, multicentre trial of 28 patients reported that tocilizumab, given at a dose of 8 mg/kg fortnightly, resulted in a significant reduction in lymphadenopathy for 52% of patients after 1 year of treatment and a median follow-up of 15 months. Biochemical improvement in inflammatory markers was also noted. 17 Three small case series, using the same regimen of tocilizumab and each including 2 to 3 patients, reported an overall response rate of 100% with a followup ranging up to 4 years. [18] [19] [20] Tocilizumab has also been reported to be beneficial in PNP associated with MCD. 10 The case presented here had refractory UCD, an entity with an extreme paucity of data, owing to its rarity. The refractory UCD
was not amenable to surgery at the outset and did not respond to neoadjuvant rituximab, radiotherapy, and systemic chemotherapy with R-CHOP. The effectiveness of tocilizumab in treating MCD coupled with the pre-existing knowledge that IL-6 is dysregulated universally in MCD made the prospect of using it for UCD enticing. However, tocilizumab did not result in clinical benefit in this case. Disappointingly, there was also no clinical response of his PNP to tocilizumab.
Paraneoplastic pemphigus has been reported as an independent adverse prognostic factor in a large single-centre review of CD including 114 patients of which 62 (54%) had UCD. Of the 37 patients with PNP, 32 had UCD. 21 Though cases of refractory course of UCD have occasionally been reported, 22, 23 this report is the first of refractory UCD treated with tocilizumab, to the best of our knowledge. Since the success rate for complete surgical resection has been remarkable in UCD, data are lacking on alternate therapies for disease not amenable to resection. In this patient, tocilizumab was not effective in treating refractory UCD.
Whether association with PNP or lack of clinically significant followup confounded delineation of its true efficacy, it would be worthwhile exploring if IL-6 pathway plays as fundamental a role in UCD as is reported in MCD. This report further highlights a need for in-depth understanding of UCD and its clonal derivation and hints that some of the cases may be neoplastic right from outset.
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